NCT01043393

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

An Open Label, Safety/Efficacy Study to Assess the Potential for Adrenal Suppression Following Multiple Dosing With Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone 0.25% Topical Spray in patients with moderate to severe plaque psoriasis. The secondary objectives are to evaluate the efficacy parameters and to evaluate the adverse event (AE) profile.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Desoximetasone 0.25% spray	Desoximetasone spray applied to affected areas twice daily for 28 days

Timeline

• Start date: 2010-02-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2010-01-06
• Last updated: 2014-06-02
• Results posted: 2014-06-02

Locations

3 sites across 1 country: United States